Menu
Back to User profile » Dr Dino Amadori
Papers published by Dr Dino Amadori:
IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
Marisi G, Scarpi E, Passardi A, Nanni O, Pagan F, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P
Cancer Management and Research 2018, 10:5659-5666
Published Date: 14 November 2018
Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial
Casadei Gardini A, Scarpi E, Orlandi E, Tassinari D, Leo S, Bernardini I, Gelsomino F, Tamberi S, Ruscelli S, Vespignani R, Ronconi S, Frassineti GL, Amadori D, Passardi A
OncoTargets and Therapy 2018, 11:5261-5268
Published Date: 29 August 2018
Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas
Recine F, Bongiovanni A, Riva N, Fausti V, De Vita A, Mercatali L, Liverani C, Miserocchi G, Amadori D, Ibrahim T
OncoTargets and Therapy 2017, 10:1155-1164
Published Date: 23 February 2017
Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas
De Vita A, Mercatali L, Recine F, Pieri F, Riva N, Bongiovanni A, Liverani C, Spadazzi C, Miserocchi G, Amadori D, Ibrahim T
OncoTargets and Therapy 2016, 9:6233-6246
Published Date: 11 October 2016
Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature
Bongiovanni A, Riva N, Calpona S, Ricci M, Gunelli E, Liverani C, La Manna F, De Vita A, Monti M, Severi S, Pieri F, Amadori E, Galassi R, Cavaliere D, Zaccaroni A, Tartaglia A, Lunedei V, Gardini A, Mercatali L, Amadori D, Ibrahim T
OncoTargets and Therapy 2014, 7:1919-1926
Published Date: 20 October 2014